Dr Pearse on the BOVen Trial of BTK Inhibitor Combinations in TP53-Mutant MCL

William B. Pearse, MD, discusses the significance of the ongoing phase 2 BOVen trial in TP53-mutant mantle cell lymphoma.

Related Keywords

California ,United States ,San Diego ,Williamb Pearse , ,University Of California ,San Diego School Of Medicine ,San Diego School ,D ,Btk Inhibitors ,Patients With Relapsed Refractory Mantle Cell Lymphoma ,Cmcl ,Aboven ,Tp53 Mutation ,